Spend Less on Cardiometabolic Disease Now. Or Spend Exponentially More Later.
High-risk pregnancy complications are among the most expensive events in your book of business. A single NICU admission can cost hundreds of thousands of dollars. Cardiometabolic disease costs the U.S. over $400 billion a year: diabetes, hypertension, obesity, and cardiovascular risk. RenewRx reduces avoidable cardiometabolic escalations by improving daily care execution between visits.
// THE COST EQUATION
The Math Is Brutal. And It Compounds Every Year.
Cardiometabolic disease does not arrive all at once. It builds through a predictable pipeline of avoidable escalations: diabetes, hypertension, obesity, cardiovascular risk. Each stage is more expensive than the last. Each stage is harder to reverse.
But there has been no partner positioned to deliver that execution at scale. Until now.
High-risk pregnancy complications drive disproportionate cost across the maternity benefit. A single complicated delivery can exceed the cost of dozens of routine births.
A single NICU admission costs hundreds of thousands of dollars. Many are avoidable with better cardiometabolic management during pregnancy.
Gestational diabetes left unmanaged leads to type 2 diabetes. 2 in 10 women diagnosed with gestational diabetes develop type 2 within a decade.
Chronic diabetes, hypertension, and cardiovascular disease compound into lifetime member costs measured in millions of dollars.
The data shows that daily cardiometabolic execution during pregnancy reduces avoidable escalations at every stage of this pipeline.
The Cost of Inaction
Every unmanaged gestational diabetes case that progresses to type 2 costs your plan across the full spectrum of cardiometabolic care for the rest of that member’s life.
The cost compounds every year you wait.The intervention window during pregnancy is the most cost-effective point of interception in the entire cardiometabolic disease lifecycle.
It is also the shortest.
Daily Cardiometabolic Execution
Between Visits. At Scale.
This Is Not a Bet on Future Value.
This Is Documented Proof.
2024-2025 Retrospective Study · 116 Patients with GDM *Delivery data available for 79 patients
139 enrolled participants.
One Colorado practice.
Zero additional staff.
mg/dL
Fasting glucose reduction
in insulin-treated patients during early intervention
%
Primary cesarean delivery
vs. 27–42% published GDM benchmark
%
NICU admission
vs. 11.2–13% published GDM benchmark
%
Preterm birth
vs. 11.2% published GDM benchmark
%
Vaginal delivery
among participants with available delivery data
%
Severe macrosomia
reported in the delivery-outcomes cohort
A Partnership
That Saves Money Today.
Invest in daily cardiometabolic execution during a high-risk pregnancy now, or pay exponentially more when that same member develops chronic diabetes, hypertension, obesity, or cardiovascular disease.
// PLATFORM EXPANSION
Pregnancy Is the Entry Point. The Platform Scales.
The same infrastructure that manages diabetesin pregnancy today expands across the full cardiometabolic spectrum: diabetes, hypertension, obesity, and cardiovascular risk. The clinical model, the coaching infrastructure, and the reimbursement structure all transfer directly.
Postpartum continuity keeps member relationships active for decades. A patient engaged during pregnancy remains a managed relationship through every subsequent cardiometabolic condition.
Cost avoidance compounds as the platform expands into more cardiometabolic conditions. Each new condition addressed reduces the long-term cost trajectory of the same member population.
See the Outcomes. See the Savings.
We will show you the documented cardiometabolic outcomes, the reimbursement structure, and the cost-avoidance model. No pitch. Just proof. 30 minutes.
hello@renewrx.health
3033822447
